Video Experimental Relacionado
Updated: May 12, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Proceso de alto rendimiento de daclizumab en la esclerosis múltiple recidivante-remitente (SELECT): un ensayo
Ralf Gold1, Gavin Giovannoni, Krzysztof Selmaj
1St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. ralf.gold@ruhr-uni-bochum.de
Lancet (London, England)
|April 9, 2013
Resumen
Daclizumab HYP redujo significativamente las tasas de recaída en pacientes con esclerosis múltiple recidivante-remitente durante un año. Este estudio sugiere daclizumab HYP como una nueva opción de tratamiento potencial para la EM activa.
Área de la Ciencia:
- Inmunología Inmunología.
- Neurología Neurología.
- Farmacología Farmacología.
Sus antecedentes:
- Daclizumab es un anticuerpo monoclonal dirigido a la subunidad alfa del receptor IL-2 (CD25).
- Modula la señalización de la interleucina-2, crucial en las respuestas inmunes.
- Este estudio investigó el proceso de alto rendimiento (HYP) de daclizumab para la esclerosis múltiple recidivante-remitente (EMRR).
Objetivo del estudio:
- Evaluar la eficacia de daclizumab HYP como monoterapia en pacientes con EMRR.
- Para evaluar su efecto sobre la actividad de la enfermedad durante un período de tratamiento de 1 año.
- Para determinar si el daclizumab HYP ofrece una nueva opción terapéutica para la EMRR.
Principales métodos:
- Un ensayo aleatorizado, doble ciego, controlado con placebo que involucró a 76 centros.
- Los pacientes con EMRR recibieron subcutáneamente daclizumab HYP (150 mg o 300 mg) o placebo cada 4 semanas durante 52 semanas.
- El objetivo primario fue la tasa de recaída anualizada, analizada por intención de tratar.
Principales resultados:
- Daclizumab HYP (150 mg y 300 mg) redujo significativamente la tasa de recaída anualizada en comparación con el placebo (reducción del 54% y 50%, respectivamente).
- Una mayor proporción de pacientes en los grupos de daclizumab HYP se mantuvo libre de recaídas (81% y 80%) frente al placebo (64%).
- Los eventos adversos graves fueron comparables entre los grupos, con una fatalidad en el grupo de daclizumab HYP 150 mg debido a una complicación de un absceso psoas.
Conclusiones:
- El daclizumab HYP administrado por vía subcutánea cada 4 semanas demostró efectos clínicamente significativos en la actividad de la enfermedad de esclerosis múltiple.
- Los hallazgos apoyan a daclizumab HYP como un tratamiento adicional potencial para la esclerosis múltiple recidivante-remitente.
- Otras investigaciones pueden explorar su eficacia a largo plazo y su perfil de seguridad.
Videos de Conceptos Relacionados
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.